安罗替尼联合治疗在肿瘤治疗中的研究进展

Research progress of anlotinib combination therapy in cancer treatment

安罗替尼是一种多靶点酪氨酸激酶抑制剂,可以通过调节肿瘤内血管的生成或改变免疫抑制微环境,发挥其抗肿瘤作用。安罗替尼已批准应用于非小细胞肺癌、软组织肉瘤、小细胞肺癌等多种类型肿瘤的临床治疗,并且在部分晚期或复发的患者取得一定治疗效果。多项临床研究发现安罗替尼与化疗、放疗、免疫检查点抑制剂等联合治疗可以显著抑制肿瘤,其治疗效果明显优于安罗替尼单药应用。论文对安罗替尼的作用机制及其在肿瘤中的联合治疗研究进展进行综述。

Anlotinib is a multi-targeting tyrosine kinase inhibitor that can play an anti-tumor role by regulating angiogenesis in cancer or an immunosuppressive microenvironment.Anlotinib shows therapeutic effects in patients with advanced or recurrent cancer and has been approved for the clinical treatment of non-small cell lung cancer,soft tissue sarcoma,small cell lung cancer,medullary thyroid cancer,and other types of tumors.Clinical studies have found that anlotinib combined with chemotherapy,radiotherapy,and immune-checkpoint inhibitors could inhibit tumor growth and showed significantly better therapeutic effects than anlotinib monotherapy.In this article,we review the mechanism of action of anlotinib and the progress in research on anlotinib in combination with other cancer treatments.